Nicholas A Butowski Selected Research

Malignant Mesothelioma

12/2016

Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas A Butowski Research Topics

Disease

22	Glioblastoma (Glioblastoma Multiforme) 10/2022 - 04/2006
17	Neoplasms (Cancer) 01/2022 - 03/2006
11	Glioma (Gliomas) 01/2022 - 03/2006
3	Brain Neoplasms (Brain Tumor) 01/2021 - 03/2006
2	Disease Progression 01/2016 - 09/2010
2	Lymphopenia (Lymphocytopenia) 01/2014 - 08/2010
1	Vision Disorders (Hemeralopia) 07/2021
1	Oligodendroglioma 07/2021
1	Cognitive Dysfunction 07/2021
1	Intraoperative Complications 08/2017
1	Malignant Mesothelioma 12/2016
1	Meningioma (Meningiomas) 12/2016
1	Pancreatic Neoplasms (Pancreatic Cancer) 12/2016
1	Neurocytoma 01/2016
1	Wounds and Injuries (Trauma) 06/2011
1	Infections 06/2011
1	Vascular Remodeling 01/2011
1	Fatigue 08/2010
1	Thrombocytopenia (Thrombopenia) 08/2010
1	Leukopenia 08/2010
1	Hemorrhage 08/2010
1	Carcinogenesis 04/2006
1	Necrosis 03/2006
1	Astrocytoma (Pilocytic Astrocytoma) 03/2006

Drug/Important Bio-Agent (IBA)

10	Bevacizumab (Avastin)FDA Link 01/2022 - 06/2011
5	Pharmaceutical PreparationsIBA 01/2021 - 09/2010
4	Temozolomide (Temodar)FDA LinkGeneric 08/2015 - 09/2010
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 09/2010
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 07/2014
2	Angiogenesis InhibitorsIBA 01/2011 - 08/2010
1	carotuximabIBA 01/2022
1	infigratinibIBA 01/2022
1	poly ICLCIBA 01/2022
1	VaccinesIBA 01/2022
1	InterferonsIBA 01/2019
1	pembrolizumabIBA 01/2019
1	palbociclibIBA 11/2018
1	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 03/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	Irinotecan (Camptosar)FDA LinkGeneric 01/2017
1	Biological ProductsIBA 12/2016
1	AntigensIBA 12/2016
1	MesothelinIBA 12/2016
1	2,2- dimethyl- N- (6- oxo- 6,7- dihydro- 5H- dibenzo(b,d)azepin- 7- yl)- N'- (2,2,3,3,3- pentafluoropropyl)malonamideIBA 12/2016
1	SaltsIBA 01/2016
1	O(6)-Methylguanine-DNA MethyltransferaseIBA 09/2014
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 07/2014
1	ErbB Receptors (EGF Receptor)IBA 07/2014
1	Peptides (Polypeptides)IBA 01/2014
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2014
1	Indicators and Reagents (Reagents)IBA 01/2011
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 08/2010
1	pazopanib FDA Link 08/2010
1	Tyrosine Kinase InhibitorsIBA 08/2010
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2010

Therapy/Procedure

12	Therapeutics 10/2022 - 03/2006
6	Drug Therapy (Chemotherapy) 07/2021 - 04/2006
5	Radiotherapy 07/2021 - 03/2006
4	Immunotherapy 01/2022 - 01/2014
2	Re-Irradiation 09/2019 - 03/2006
2	Aftercare (After-Treatment) 05/2019 - 09/2013
2	Craniotomy 02/2012 - 06/2011
1	Adjuvant Chemotherapy 07/2021
1	Chemoradiotherapy 08/2017
1	Adjuvant Radiotherapy 01/2016
1	Duration of Therapy 06/2011
1	Drug Tapering 08/2010
1	Photochemotherapy (Photodynamic Therapy) 03/2006
1	Brachytherapy 03/2006
1	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 03/2006